Allergan pulls Europe, Japan application for wet macular degeneration drug

AbbVie (NYSE:ABBV) unit Allergan has informed Molecular Partners (OTCPK:MLLCF) of its intent to withdraw application filings with both the European Medicines Agency and the Japanese Regulatory Agency for abicipar pegol, a novel DARPin therapeutic for patients with neovascular (wet) age-related macular degeneration (nAMD).

On June 26, the FDA rejected Allergan’s application for the wet AMD drug, following which AbbVie is working with the regulatory agencies to discuss requirements for potential resubmissions for abicipar pegol.

https://seekingalpha.com/news/3592463-allergan-pulls-back-european-and-japanese-application-for-wet-amd-drug